Pharmaceutical Processing

The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News

Subscribe to Pharmaceutical Processing
View Sample

FREE Daily Email Newsletter

Ranbaxy Agrees to $500M Penalty

May 13, 2013 3:25 pm | by ERIC TUCKER,Associated Press | News | Comments

A subsidiary of India's largest pharmaceutical company has agreed to pay $500 million in fines and civil penalties for selling adulterated drugs and lying about tests of the medications to federal regulators, the U.S. Justice Department said Monday.

TOPICS:

Kilo-lab Size Conical Vacuum Dryer/Mixer

May 13, 2013 3:19 pm | Product Releases | Comments

Kilo-lab size conical vacuum dryer/mixer machine matches the special requirements in the lab with regard to the software program data recording, measurement points, outfit and use, and offers modular design, maximum flexibility and mobility, applications can be carried out on drying processes under vacuum and other procedures such as mixing and homogenizing, degassing, moistening and so forth.

Omnitronics Freeze Dryer

May 13, 2013 3:07 pm | Product Releases | Comments

The VirTis Benchtop Pro with Omnitronics freeze dryer has been engineered with the research scientist in mind. Traditional time losses incurred from lengthy condenser defrost and clean-up procedures are minimized with the new hot-gas defrost facility on the BenchTop Pro.

Advertisement

Filtration and Drying Process

May 13, 2013 2:25 pm | Product Releases | Comments

The simplefilter is designed for many pharmaceutical applications such as: hydrogenation, carbon filtration, catalyst recovery, pre-filter for micro-filtration, APIs and intermediate filtration.

Mixer/Dryer/Cooler

May 13, 2013 1:00 pm | Product Releases | Comments

The Bella Series 543 mixer/dryer/cooler offers an improved method for drying or cooling  powders, granulates and filter cakes. The Bella dryer can be used for drying, mixing, spraying, agglomerating and cooling in the same unit without additional equipment or costs.

Dry Powder Blending System

May 13, 2013 12:19 pm | Product Releases | Comments

The blending system allows homogeneous blending of dry powder batches with its patented blending elements mounted to the inside of the container lid. The blending procedure can be scaled up from 4 – 12,000 liters.

Aptamer Protein Precipitation Kits

May 13, 2013 11:34 am | Product Releases | Comments

The new range of Aptamer Protein Precipitation Kits bind with unmatched high specificity and affinity to target molecules. The new Aptoprecipitation (AP) / Co-aptoprecipitation (Co-AP) Kits are aptamer based protein precipitation kits designed to provide easy, quick and consistent protein precipitation.

Labor Drug Study Triggers Mommy-Blog Firestorm

May 13, 2013 8:49 am | Videos | Comments

A new study about a popular drug used to help so many moms speed up labor and could have some potentially negative effects. According to researchers, pitocin showed a potential link to some full term infants having increased admissions to neonatal intensive care units.

Advertisement

Government Stops Study Seeking To Prevent Type of Stroke

May 13, 2013 8:38 am | by LAURAN NEERGAARD,AP Medical Writer | News | Comments

The government has halted a study testing treatments for a brain condition that can cause strokes after early results suggested invasive therapies were riskier than previously thought. The condition involves a kind of tangle in the brain called an arteriovenous malformation, or AVM. Arteries and veins grow knotted together until eventually some of them burst, causing a bleeding stroke.

TOPICS:

FDA Accepts Biogen Idec’s BLA for Long-Lasting Factor VIII Therapy for Hemophilia A

May 13, 2013 8:31 am | News | Comments

Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the marketing approval of ELOCTATE™ (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A.

TOPICS:

Huge Drug Cost Disparities Seen in Health Overhaul

May 13, 2013 8:27 am | by RICARDO ALONSO-ZALDIVAR,Associated Press | News | Comments

Cancer patients could face high costs for medications under President Barack Obama's health care law, industry analysts and advocates warn. Where you live could make a huge difference in what you'll pay. To try to keep premiums low, some states are allowing insurers to charge patients a hefty share of the cost for expensive medications used to treat cancer, multiple sclerosis, rheumatoid arthritis and other life-altering chronic diseases.

TOPICS:

Frazier Healthcare Acquires AndersonBrecon from AmerisourceBergen

May 13, 2013 8:17 am | News | Comments

Frazier Healthcare and Packaging Coordinators, Inc. today announced that they have completed the acquisition of pharmaceutical packager AndersonBrecon from its parent company AmerisourceBergen Corporation. AndersonBrecon will now merge with and operate as Packaging Coordinators, Inc.

TOPICS:

Elan Enters $1B Royalty Deal with Theravance

May 13, 2013 8:12 am | by The Associated Press | News | Comments

Irish drugmaker Elan plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance and GlaxoSmithKline. The deal will give Elan 21 percent of the future royalties that Theravance Inc. receives from Glaxo. Theravance shares jumped 7 percent in premarket trading. Elan shares slipped.

TOPICS:

FDA Denies Request to Block Generic Painkiller

May 10, 2013 5:53 pm | by The Associated Press | News | Comments

In a surprise move Friday, federal health regulators denied a request by Endo Health Solutions to block generic versions of its painkiller Opana ER, which the company argued are more easily abused than its branded product. Endo's Opana ER is a long-acting narcotic drug used to treat moderate and...

TOPICS:

Actavis, Warner Chilcott Discussing Combination

May 10, 2013 3:38 pm | by MARLEY SEAMAN - AP Business Writer - Associated Press | News | Comments

The drugmakers Actavis Inc. and Warner Chilcott PLC say they are holding early discussions about a possible combination of the two companies. The companies say there is no guarantee that Actavis will make an offer for Warner Chilcott, however. Actavis expects to generate more than $8.1 billion...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading